GenMark's Q1 Revenues Nearly Double

During a conference call, the company's chairman said that GenMark expects to file for FDA approval on three tests for upper respiratory viruses, hepatitis C, and KRAS mutations.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories